Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745885 | 1.00 | PRKCQ (0.39) | PRKCQEGFRSYKJAK2RET | |
| SCHEMBL24539065 | 0.87 | PRKCQ (0.39) | PRKCQEGFRSYK | |
| SCHEMBL30629380 | 0.87 | PRKCQ (0.39) | PRKCQEGFRSYK | |
| SCHEMBL29745850 | 0.86 | EGFR (0.36) | PRKCQEGFRSYKPRKCDESR1 | |
| SCHEMBL24539075 | 0.86 | EGFR (0.36) | PRKCQEGFRSYKPRKCDESR1 | |
| SCHEMBL24539089 | 0.86 | ATR (0.35) | PRKCQEGFRSYKJAK2LRRK2 | |
| SCHEMBL29745957 | 0.86 | ATR (0.35) | PRKCQEGFRSYKJAK2LRRK2 | |
| SCHEMBL24539066 | 0.86 | EGFR (0.51) | PRKCQEGFRPRKCD | |
| SCHEMBL29745814 | 0.86 | EGFR (0.51) | PRKCQEGFRPRKCD | |
| SCHEMBL29745767 | 0.85 | GPR119 (0.38) | SYKJAK2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076285-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-07 | — | — | US | disclosed |
| CN-117222634-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022133046-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076285-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PRKCQ 107/4885EGFR 1429/4885SYK 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.